A Phase 1, Double-Masked, Randomized, Safety and Efficacy, Single Center Clinical Evaluation of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy (HCEC-1) in Adult Subjects With Corneal Edema Secondary to Endothelial Dysfunction
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Neltependocel (Primary) ; Y 27632 (Primary)
- Indications Corneal disorders; Oedema
- Focus Adverse reactions
- Acronyms Escalon
- Sponsors Aurion Biotech
Most Recent Events
- 03 Sep 2024 According to an Aurion Biotech Media Release, clinical data from this trial will be presented at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) to be held September 6-10, 2024 in Barcelona, Spain.
- 02 Apr 2024 According to Aurion Biotech Media Release, data from the study will be presented at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.